Novartis AG remains in pole position with its RNA interference (RNAi) therapy inclisiran after results from rival Arrowhead Pharmaceuticals Inc. fell short of challenging its results in lipid-lowering.
The Swiss big pharma company jumped into the field last year when it acquired The Medicines Co. for $9.7bn...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?